OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting
Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June. Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.…
OS02: Evaluating public health interventions: a neglected area in HTA field
Public health interventions are important for ensuring sustainable healthcare infrastructures, but represent a neglected area in HTA due to various methodological issues and complex design that frequently goes beyond clinically oriented interventions. This presentation will include the results of a cross-sectional survey that aimed to provide a global mapping of HTA initiatives related to the assessment of public health technologies, co-authored by Grace Hampson.
PS32: Adapting HTA and procurement to tackle antimicrobial resistance
There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance, but there is little agreement on how. This poster, co-authored by Adrian, Margherita, Grace, and OHE Visiting Fellow Chris Henshall, reports findings from a literature review, expert interviews, and face-to-face discussions at a forum.
PS32: Value-based policies to support innovations in precision medicine
This policy paper, co-authored by Adrian, proposes principles to support dynamic efficiency in the development, adoption, and use of personalised and precision medicine. These principles define the need for a broader concept of value; flexible, value-based, indication-specific pricing of complementary diagnostic tests and medicines; ongoing real-world evidence generation; and appropriate methods to divide and reward value among complementary diagnostic tests and medicines.
OS19: Aligning value in regulatory and health technology assessments
The recent proliferation of value assessment frameworks with a range of approaches and methods has confused many potential users. This policy analysis, co-authored by Adrian, explores their differences and similarities. Four key decision contexts—regulatory benefit-risk analysis, coverage and reimbursement, treatment guidelines and clinical pathways, and clinical shared decision-making—can be aligned by using the quality-adjusted life year as the central value element.
PS39: Quantifying the life-cycle value of innovative medicines: the case of risperidone and second-generation antipsychotics
This work, led by Mikel, quantifies the value added by risperidone (second-generation antipsychotic) versus haloperidol (first-generation antipsychotic) along its life-cycle. The authors estimate the consumer and producer surplus, the net monetary benefit and the incremental cost-effectiveness ratio, per year and aggregated (1994-2017). Results suggest that market access decisions at launch should consider the value added by innovative medicines over their entire life-cycle.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!